BridgeMD
mFBG PET-CT scan for the imaging of pheochromocytoma
EU CTIS ID: 2024-513622-35-00
What this study is testing
The primary objective of this study is to assess the number of detected pheochromocytoma lesions, proved by histology, with [18F]mFBG PET-CT compared to the conventional CT.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - The patient has provided written informed consent authorization before participating in the study. - The patient is ≥18 years of age at the time of consent. - The patient has a diagnosis of pheochromocytoma with a known anatomical location or laboratory findings suspicious for pheochromocytoma defined as elevated serum/plasma metanefrines. - The patient should have surgery planned. - The patient should have had a CT scan not older than 8 weeks at time of the [18F]mFBG PET-CT.. - The patient has an ECOG status of Grade 0 – 2.
You likely can't join if
- - Patient is mentally or legally incapacitated. - Patient is pregnant or lactating. - Patient has active serious infections not controlled by antibiotics. - Patient is unable or unwilling to undergo PET-CT scanning or surgery. - Patient did receive interfering treatment between conventional CT scanning and [18F]mFBG PET-CT.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.